Valuation: Abeona Therapeutics Inc.

Market Cap 260M 233M 216M 195M 365M 24.78B 370M 2.58B 1.03B 12.97B 976M 956M 41.17B P/E 2026 *
-4.63x
P/E 2027 * -22.8x
Enterprise Value 260M 233M 216M 195M 365M 24.78B 370M 2.58B 1.03B 12.97B 976M 956M 41.17B EV / Sales 2026 *
4.94x
EV / Sales 2027 * 2.25x
Free-Float
83.76%
Yield 2026 *
-
Yield 2027 * -
1 day+2.25%
1 week+0.89%
Current month-13.33%
1 month-13.99%
3 months-24.42%
6 months-15.11%
Current year-13.66%
1 week 4.29
Extreme 4.29
4.58
1 month 4.28
Extreme 4.28
5.33
Current year 4.23
Extreme 4.23
7.65
1 year 4
Extreme 4
7.65
3 years 3.05
Extreme 3.05
9.01
5 years 2.19
Extreme 2.19
26.5
10 years 2.19
Extreme 2.19
568.75
Manager TitleAgeSince
Chief Executive Officer 50 2021-10-14
Director of Finance/CFO 42 2022-03-13
Chief Tech/Sci/R&D Officer - 2025-10-19
Director TitleAgeSince
Director/Board Member 58 2006-02-28
Director/Board Member 64 2021-03-24
Director/Board Member 63 2021-04-18
Date Insider Type Main position Quantity % Market Cap. Importance
9/29/26 Sell

Chief Executive Officer

-19,608 0.0343%
9/29/26 Sell

General Counsel

-6,727 0.0118%
9/29/26 Sell

Executive/Senior Manager

-4,902 0.0086%
Change 5-day change 1-year change 3-year change Capi.($)
+2.25%+0.89%-13.83%+22.64% 260M
+0.50%+1.38%+57.09%+129.96% 1,148B
+0.86%+5.14%+45.00%+86.15% 652B
-0.14%+0.42%+25.69%+105.85% 505B
+0.44%+2.07%+53.69%+65.85% 384B
-0.63%-5.97%+61.93%+37.06% 348B
+2.27%+2.48%+34.09%+56.07% 294B
+0.92%-0.77%+2.55%+26.05% 264B
+0.87%+3.08%+54.69%+72.74% 244B
+0.08%+3.67%+35.05%+107.78% 197B
Average +0.74%+1.34%+35.59%+71.02% 403.74B
Weighted average by Cap. +0.54%+1.50%+44.84%+89.05%

Financials

2026 *2027 *
Net sales 52.63M 47.22M 43.66M 39.54M 73.87M 5.01B 74.76M 522M 208M 2.62B 198M 193M 8.33B 116M 104M 95.91M 86.86M 162M 11.01B 164M 1.15B 457M 5.76B 434M 425M 18.29B
Net income -56.16M -50.39M -46.59M -42.19M -78.83M -5.35B -79.78M -557M -222M -2.8B -211M -206M -8.89B -11.39M -10.22M -9.45M -8.55M -15.98M -1.08B -16.17M -113M -44.98M -567M -42.73M -41.83M -1.8B
Net Debt - -
Projected Income Statement - Annual - Abeona Therapeutics Inc.
Logo Abeona Therapeutics Inc.
Abeona Therapeutics Inc. is a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases. The Company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa. Its fully integrated cell and gene therapy cGMP manufacturing facility in Cleveland, Ohio serves as the manufacturing site for ZEVASKYN commercial production. Its development portfolio features adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need. Its AAV capsids are being evaluated to improve tropism profiles for a variety of devastating diseases. Its pipeline programs include ABO-504 (Stargardt disease), ABO-503 (X-linked retinoschisis), ABO-505 (autosomal dominant optic atrophy), UX111 (Sanfilippo Syndrome Type A (MPS IIIA)), TSHA-102 (Rett Syndrome), and TSHA-118 (Infantile Batten Disease (CLN1 Disease)).
Employees
226
Date Price Change Volume
26-10-28 US$4.550 +2.25% 618,145
26-10-27 US$4.450 +3.25% 663,678
26-10-26 US$4.310 -2.05% 426,579
26-10-23 US$4.400 -1.57% 797,293
26-10-22 US$4.470 -0.89% 717,808
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Abeona Therapeutics Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
4.550USD
Average target price
18.88USD
Spread / Average Target
+314.84%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Abeona Therapeutics Inc.
  1. Stock Market
  2. Stocks
  3. ABEO Stock